Champions Oncology Inc - Asset Resilience Ratio
Champions Oncology Inc (CSBR) has an Asset Resilience Ratio of 0.00% as of October 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read CSBR current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2018)
This chart shows how Champions Oncology Inc's Asset Resilience Ratio has changed over time. See net assets of Champions Oncology Inc for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Champions Oncology Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CSBR market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Champions Oncology Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Champions Oncology Inc Industry Peers by Asset Resilience Ratio
Compare Champions Oncology Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Champions Oncology Inc (2009–2018)
The table below shows the annual Asset Resilience Ratio data for Champions Oncology Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-04-30 | 0.00% | $0.00 | $8.08 Million | -- |
| 2017-04-30 | 0.00% | $0.00 | $8.01 Million | -- |
| 2016-04-30 | 0.00% | $0.00 | $5.78 Million | -- |
| 2015-04-30 | 0.00% | $0.00 | $12.05 Million | -- |
| 2014-04-30 | 0.00% | $0.00 | $8.87 Million | -- |
| 2013-04-30 | 0.00% | $0.00 | $11.69 Million | -- |
| 2012-04-30 | 0.00% | $0.00 | $6.92 Million | -- |
| 2009-04-30 | 22.01% | $1.02 Million | $4.62 Million | -- |
About Champions Oncology Inc
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft technology platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers translational oncology solutions that utilizes its technology platform … Read more